Unless otherwise noted, speakers have nothing to disclose.

Moderators

Melanie Edwards, MD
Disclosure(s): Astra Zeneca: Advisory Board (Terminated)

Smita Sihag, MD, MPH

Presentations

1. Interval Changes in Skeletal Muscle Index are Predictive of Overall Survival and Disease-Free Survival in Patients with Esophageal Cancer Undergoing Trimodality Therapy
   Uzair M. Jogiat, MD
    
2. Food Deserts Increase Readmission Following Tri-Modality Therapy for Esophageal Cancer: A Multi-Institutional Study
   Joseph D. Phillips, MD
    
3. Transcriptomic analysis of esophageal adenocarcinoma archived surgical samples with NanoString PanCancer panels reveals ANPEP/CD13 is associated with lymphovascular invasion and survival.
   Wayne Hofstetter, MD
    
4. Immunotherapy - Evolving Role in Treating Esophageal Cancer
   Matthew Strickland, MD
    
5. Expert Panel—Esophageal Cancer Surgery in the Immunotherapy Era
   Daniela Molena, MD
   Disclosure: Medtronic: Speaker (Ongoing); Astra Zeneca: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scientific: Consultant (Ongoing), Speaker (Ongoing); Edwards Life Science, Abbott, Medtronic, AtriCure, Johnson and Johnson, ClearFlow: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
   
   Matthew Strickland, MD
   
   Rishindra M. Reddy, MD, MBA
   Disclosure: Medtronic: Advisory Board (Terminated, October 1, 2022); AtriCure: Advisory Board (Ongoing); DaVinci Intuitive Surgical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genentech: Advisory Board (Ongoing); On Target Laboratories: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, October 1, 2022)